Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: A tale of T cells and antibodies

AIDS

Volumn 24, Issue 6, 2010, Pages 803-809

  D'Souza, M Patricia ^a   Frahm, Nicole ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Adenovirus; HIV 1 vaccines; Preexisting immunity

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MULTIPLE EPITOPE THROMBOSPONDIN RELATED ADHESION PROTEIN; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; HUMAN; HUMAN ADENOVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; NONHUMAN; NOTE; PRIORITY JOURNAL; SEROTYPE; VIRUS IMMUNITY;

ADENOVIRIDAE; AIDS VACCINES; ANTIBODIES, VIRAL; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION;

EID: 77949564415     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283379712     Document Type: Note

References (31)

1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1894-1905.
2. Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, Gall JG, et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 2009; 83:6318-6322.
3. Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, Ratcliffe SJ, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4R T cells. Nat Med 2009; 15:876-878.
4. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009; 15:873-875.
5. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
6. FrahmN,De Rosa SC, Defawe OD, Carter DK, Janes H, Moodie Z, et al. HIV infected cases have lower preinfection Ad5-specific T-cell response rates than noncases after Ad5/HIV vaccination in the Step trial. AIDS Vaccine Meeting. Cape Town, South Africa; 2008.
7. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008; 205:2717-2725.
8. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46:1769-1781.
9. Cheng C, Gall JGD, Nason M, King CR, Koup RA, Roederer M, et al. Differential specificity and immunogenicity of adenovirus 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 2010; 84:630-638.
10. Johnston MI, Fauci AS. An HIV vaccine: challenges and prospects. N Engl J Med 2008; 359:888-890.
11. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, Hayes P, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009; 106:19940-19945.
12. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6:1574-1583.
13. Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002; 76:10608-10616.
14. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004; 18:1213-1216.
15. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, et al. Neutralizing antibodies to adenovirus sero-type 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174:7179-7185.
16. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008; 82:4844-4852.
17. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogeni-city of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81:4654-4663.
18. Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimber-gen J, Kaspers J, et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and noncross-reactivity with Ad5. J Virol 2004; 78:13207-13215.
19. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent preexisting antivector immunity. Nature 2006; 441:239-243.
20. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.
21. Ebner K, Pinsker W, Lion T. Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol 2005; 79:12635-12642.
22. Berk AJ. Adenoviridae:the virusesandtheir replication. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. pp. 2355-2394.
23. Friedrich DP, Frahm N, Campbell RL, Schurtz E, Spies AG, Vogt J, et al. Adenovirus serotype 5-specific T cells preferentially recognize conserved regions across multiple adenovirus ser-otypes. Keystone 'Prevention of AIDS' Symposium. Keystone, CO; 2009.
24. Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther 1998; 9:1419-1427.
25. Leen AM, Sili U, Vanin EF, Jewell AM, Xie W, Vignali D, et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8R T cells. Blood 2004; 104:2432-2440.
26. Leen AM, Sili U, Savoldo B, Jewell AM, Piedra PA, Brenner MK, Rooney CM. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2004; 103:1011-1019.
27. Calcedo R, Vandenberghe LH, Roy S, Somanathan S, Wang L, Wilson JM. Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 2009; 83:2623-2631.
28. Tatsis N, Lasaro MO, Lin SW, Xiang ZQ, Zhou D, Dimenna L, et al. Adenovirus vector-induced immune responses in non-human primates: responses to prime boost regimens. J Immunol 2009; 182:6587-6599.
29. Folgori A, Barnes E, Aston S, Smith K, Ambrosio M, Ammendola V, et al. Phase I Trial of a highly immunogenic T cell vaccine for hepatitis C virus based on novel, rare, adenoviral vectors [abstract # 44]. 16th International Symposium on Hepatitis C Virus and Related Viruses. Nice, France; 3-7 October 2009.
30. Excler JL, Rida W, Priddy F, Fast P, Koff W. A strategy for accelerating the development of preventive AIDS vaccines. AIDS 2007; 21:2259-2263.
31. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886-892.